Inhibitor outperforms rivals in leukemia, lymphoma

Print Friendly, PDF & Email


Researchers in the lab
Photo by Rhoda Baer
Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain hematologic malignancies. In one study, CG’806 proved more potent than comparator drugs in primary samples of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). In another study,... [Read Article]
Print Friendly, PDF & Email

Research reveals new subtypes of DLBCL

Print Friendly, PDF & Email


Micrograph showing DLBCL
New research helps explain why some patients with diffuse large B-cell lymphoma (DLBCL) respond well to immunochemotherapy and others do not. Researchers analyzed samples from nearly 600 DLBCL patients and identified 4 new genetic subtypes of the disease. Patients with 2 of these subtypes had overall survival (OS) rates that were roughly... [Read Article]
Print Friendly, PDF & Email

Tazemetostat exhibits antitumor activity in phase 1 trial

Print Friendly, PDF & Email


Micrograph showing DLBCL
The EZH2 inhibitor tazemetostat demonstrated a “favorable safety profile and antitumor activity” in a phase 1 study, according to researchers. The drug produced responses in 8 of 21 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), including 3 complete responses (CRs). The maximum tolerated dose of tazemetostat was not reached, and there were... [Read Article]
Print Friendly, PDF & Email

Combo improves outcomes in MCL

Print Friendly, PDF & Email


Venetoclax and ibrutinib
Photo from Peter
MacCallum Cancer Centre
A 2-drug combination can improve outcomes in patients with mantle cell lymphoma (MCL), according to researchers. In a phase 2 trial of MCL patients, the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax produced an overall response rate of 71% and a complete response (CR)... [Read Article]
Print Friendly, PDF & Email

Tenalisib receives orphan designation for CTCL

Print Friendly, PDF & Email


Micrograph showing
mycosis fungoides
The US Food and Drug Administration (FDA) has granted orphan drug designation to tenalisib for treatment of cutaneous T-cell lymphoma (CTCL). Tenalisib (formerly RP6530) is a dual PI3K delta/gamma inhibitor under development by Rhizen Pharmaceuticals SA. The FDA previously granted tenalisib fast track and orphan drug designations for the treatment... [Read Article]
Print Friendly, PDF & Email

Duvelisib NDA granted priority review

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for duvelisib, a dual PI3K delta/gamma inhibitor. With this NDA, Verastem, Inc., is seeking full approval of duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval... [Read Article]
Print Friendly, PDF & Email

Drug receives priority review for HCL

Print Friendly, PDF & Email


Hairy cell leukemia
Image from Paulo
Henrique Orlandi Mourao
The US Food and Drug Administration (FDA) has accepted for priority review the biologics license application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin. With this BLA, AstraZeneca is seeking approval for moxetumomab pasudotox for the treatment of adults with hairy cell leukemia... [Read Article]
Print Friendly, PDF & Email

ICER assesses value of CAR T-cell therapies

Print Friendly, PDF & Email


Tisagenlecleucel (Kymriah)
Photo from Novartis
The Institute for Clinical and Economic Review (ICER) has made policy recommendations intended to ensure affordability and access to chimeric antigen receptor (CAR) T-cell therapies. ICER released a Final Evidence Report on tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead), 2 CAR T-cell therapies approved in the US... [Read Article]
Print Friendly, PDF & Email